Xencor (NASDAQ:XNCR) Issues Quarterly Earnings Results

Xencor (NASDAQ:XNCR) released its earnings results on Wednesday. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($1.06), FiscalAI reports. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million.

Xencor Price Performance

XNCR stock traded up $0.16 on Wednesday, reaching $13.01. The company had a trading volume of 818,951 shares, compared to its average volume of 784,554. Xencor has a 1 year low of $6.92 and a 1 year high of $18.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The company’s fifty day moving average is $12.24 and its 200 day moving average is $13.63. The company has a market cap of $964.43 million, a P/E ratio of -10.49 and a beta of 0.93.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wall Street Zen upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 target price (down from $18.00) on shares of Xencor in a research report on Tuesday, March 24th. Barclays boosted their target price on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.38.

Insider Activity at Xencor

In related news, CEO Bassil I. Dahiyat sold 6,606 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $72,798.12. Following the sale, the chief executive officer owned 546,316 shares of the company’s stock, valued at approximately $6,020,402.32. This represents a 1.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP John R. Desjarlais sold 2,502 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $27,572.04. Following the completion of the sale, the vice president directly owned 263,831 shares in the company, valued at approximately $2,907,417.62. The trade was a 0.94% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 44,020 shares of company stock valued at $499,817. 5.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its holdings in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. acquired a new stake in Xencor in the 2nd quarter valued at $79,000. iSAM Funds UK Ltd acquired a new stake in Xencor in the 2nd quarter valued at $122,000. Prelude Capital Management LLC acquired a new stake in Xencor in the 3rd quarter valued at $139,000. Finally, Creative Planning increased its holdings in Xencor by 25.3% in the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,661 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.